LeMaitre Vascular (NASDAQ:LMAT) Issues Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• LeMaitre Vascular reported earnings of $0.60 per share, exceeding expectations by $0.03, with a year-over-year revenue increase of 15%.
• The company's stock rose by 1.5% to $85.60, following the earnings release, with a market capitalization of $1.93 billion.
• Insider activity showed CEO George W. Lemaitre sold 4,399 shares, reducing his stake by 0.24%, while institutional investors own 84.64% of the company.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) released its quarterly earnings results on Tuesday. The medical instruments supplier reported $0.60 EPS for the quarter, topping the consensus estimate of $0.57 by $0.03, Zacks reports. The firm had revenue of $63.15 million during the quarter, compared to analyst estimates of $62.48 million. LeMaitre Vascular had a return on equity of 13.91% and a net margin of 20.08%. The business's revenue for the quarter was up 15.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.52 EPS. LeMaitre Vascular updated its Q3 2025 guidance to 0.540-0.590 EPS and its FY 2025 guidance to 2.230-2.370 EPS.

LeMaitre Vascular Stock Performance

LeMaitre Vascular stock traded up $1.03 during trading hours on Thursday, hitting $94.26. 296,181 shares of the stock traded hands, compared to its average volume of 189,972. The company has a debt-to-equity ratio of 0.48, a current ratio of 16.49 and a quick ratio of 13.83. The firm's 50 day moving average price is $82.88 and its 200-day moving average price is $86.73. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of 45.76, a P/E/G ratio of 2.26 and a beta of 0.79. LeMaitre Vascular has a 1 year low of $71.42 and a 1 year high of $109.58.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.8%. The ex-dividend date is Thursday, August 21st. LeMaitre Vascular's payout ratio is presently 40.40%.

Insiders Place Their Bets

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 4,399 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total transaction of $374,354.90. Following the sale, the chief executive officer owned 1,827,003 shares in the company, valued at approximately $155,477,955.30. The trade was a 0.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 100,000 shares of company stock worth $8,556,857. 9.50% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

Several hedge funds and other institutional investors have recently bought and sold shares of LMAT. Geneos Wealth Management Inc. raised its holdings in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 398 shares during the period. Strs Ohio purchased a new position in LeMaitre Vascular during the first quarter worth approximately $168,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in LeMaitre Vascular by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier's stock worth $1,013,000 after purchasing an additional 539 shares in the last quarter. Jane Street Group LLC boosted its position in LeMaitre Vascular by 738.7% during the first quarter. Jane Street Group LLC now owns 20,096 shares of the medical instruments supplier's stock worth $1,686,000 after purchasing an additional 17,700 shares in the last quarter. Finally, Intech Investment Management LLC boosted its position in LeMaitre Vascular by 116.6% during the first quarter. Intech Investment Management LLC now owns 20,967 shares of the medical instruments supplier's stock worth $1,759,000 after purchasing an additional 11,288 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on LMAT. Cantor Fitzgerald boosted their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday. Barrington Research upgraded LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $98.00.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.